Pivotal Trial of a Digital Therapeutic for the Treatment of Type 2 Diabetes

Phase 3

Completed

• Conditions: Type 2 Diabetes
• Interventions: Device: BT-001; Other: Physician-guided Standard of Care for type 2 diabetes

• Registration Number: NCT04886388
• Lead Sponsor: Better Therapeutics

Brief Summary

BT-001 is a software program intended to help patients with type 2 diabetes, under the guidance of their physician, improve glycemic control (i.e., levels of blood sugar). The BT-001 software delivers a type of behavioral therapy to patients via a mobile application that targets behaviors related to achieving glycemic control. The effectiveness of BT-001 will be measured by its ability to help patients reduce Hemoglobin A1c, or HbA1c (a marker in the blood that measures blood sugar) compared to standard medical care in patients with type 2 diabetes.

Detailed Description

The study will utilize an open-label, randomized, parallel-group design to confirm and characterize the safety and efficacy of BT-001 used in addition to standard of care (SOC) when compared to SOC alone in patients with type 2 diabetes. The screening period will consist of a run-in during which time HbA1c will be assessed for confirmation of eligibility.

Once confirmed to be eligible, patients will then be randomized 1:1 to the following groups:

Investigational: One half of the participants will be treated with BT-001 plus SOC for 180 days;

Control: One half of the participants will be treated with SOC alone for 180 days.

Study Timeline

• Study Start: 2021-04-22
• Study First Submitted: 2021-05-07
• Study First Submitted QC: 2021-05-10
• Study First Posted: 2021-05-14
• Status Verified: 2022-01
• Primary Completion: 2022-03-09
• Study Completion: 2022-09-27
• Last Update Submitted: 2023-09-26
• Last Update Posted: 2023-09-28

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 668

Inclusion Criteria

1. Between 18 and 75 years old, inclusive at the time of signing the informed consent;
2. Diagnosis of type 2 diabetes, according to the criteria of the American Diabetes Association (ADA), and confirmed at the initial eligibility screening;
3. Body Mass Index ≥25 kg/m2;
4. Possesses a smartphone (iPhone or Android only) capable of running the smartphone applications (Apps) used in the study;
5. Has had no change in the last 4 months prior to randomization (3 months prior to initial screening plus 30-day run-in screening period) in antihyperglycemic medications;
6. Has a current HbA1c level >7%, as determined by both screening assessments;
7. Willing to use an FDA approved glucometer for self-monitoring blood glucose throughout the study;
8. Is capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF).

Exclusion Criteria

1. Are unable to understand, consent to, or comply with the study protocol for any reason;

2. Currently taking prandial (mealtime) insulin;

3. Have self-reported measures, collected during screening interview, that reveal:

   1. An active eating disorder
   2. The taking of or planning to take (within the next 6 months):

   i. Oral steroids (planned, or within the past 3 months) ii. Chemotherapy (planned, or within the past 6 months) iii. Weight loss medications or iv. Atypical antipsychotic medications

   c. A change in antidepressant or anti-anxiety medication within the past 3 months;

   d. A history of bariatric surgery or planned bariatric surgery during the study;

   e. The current use of marijuana, cocaine, opioid painkillers, or other addictive substances;

   f. The current use of tobacco products or use of tobacco products within the past 6 months;

   g. The consumption of alcohol above defined thresholds:

   i. For women: more than 3 drinks in a single day, or more than 7 drinks per week and ii. For men: more than 4 drinks in a single day, or more than 14 drinks per week

   h. An unstable or life-threatening medical illness;

   i. Non-resolved, presumed or confirmed COVID-19 diagnosis prior to randomization or during primary study period;

   j. For women only: pregnant (or lactating) or having the intention of becoming pregnant during the time frame of the study.

4. Has a current HbA1c level ≥11%, at the screening assessment;

5. Concurrent enrollment in any other clinical trial;

6. Is considered unreliable by the investigator, or having any condition which, in the opinion of the investigator, would not allow safe participation in the study.

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
BT-001 + Standard of Care	BT-001	BT-001 is a software program used with physician guidance, being investigated to improve glycemic control. Patients randomized to this arm of the study will interact with the BT-001 software program in addition to receiving Standard of Care for type 2 diabetes
Standard of Care	Physician-guided Standard of Care for type 2 diabetes	Patients randomized to the Standard of Care arm will receive Standard of Care treatment for type 2 diabetes under the guidance of a physician
BT-001 + Standard of Care	Physician-guided Standard of Care for type 2 diabetes	BT-001 is a software program used with physician guidance, being investigated to improve glycemic control. Patients randomized to this arm of the study will interact with the BT-001 software program in addition to receiving Standard of Care for type 2 diabetes

Primary Outcome Measures

Name	Time	Method
The difference in the mean change from baseline in HbA1c at Day 90 between Intervention and Standard of Care groups	Baseline and Day 90	Hemoglobin A1c (HbA1c) test measures the amount of blood sugar (glucose) attached to hemoglobin.

Secondary Outcome Measures

Name	Time	Method
The difference in the mean change from baseline in HbA1c at Day 180 between Intervention and Standard of Care groups	Baseline and Day 180	Hemoglobin A1c (HbA1c) test measures the amount of blood sugar (glucose) attached to hemoglobin.

Trial Locations

Locations (1)

Study Site; 🇺🇸 Houston, Texas, United States